SIMBs + Immunotherapy
Pancreatic Cancer
Pre-clinicalValidated in preclinical studies
Key Facts
Indication
Pancreatic Cancer
Phase
Pre-clinical
Status
Validated in preclinical studies
Company
About Advanced Microbubbles
Advanced Microbubbles is addressing the critical challenge of inefficient drug delivery in oncology, where less than 1% of injected drugs typically reach their target. Their core innovation is the creation of stable, large, monodisperse microbubbles that, when combined with ultrasound, can non-invasively open biological barriers to enable precise delivery of various therapeutic agents. The platform has shown promising preclinical results in models of pancreatic cancer, neuroblastoma, and for blood-brain barrier opening, positioning the company to advance a versatile, drug-agnostic delivery technology.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ARV-806 | Arvinas | Phase 1 |
| CPI-613 (devimistat) + Hydroxychloroquine | Rafael Holdings | Phase 1/2 |
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| SON-1210 | Sonnet BioTherapeutics | Phase 1/2a |